All six major UK insurers — Bupa, AXA Health, Aviva, Vitality, WPA and The Exeter — offer strong cancer cover on their comprehensive policies, typically spanning diagnosis, treatment and drugs not routinely NHS-funded. The differences live in the detail: full versus capped or NHS-linked options, aftercare, and drug funding rules. Judge policies on their cancer wording, not their headline.
- ✓Comprehensive policies from major insurers generally cover cancer from diagnosis through treatment.
- ✓Cheaper options may cap cancer benefits or link them to NHS provision — read the cancer wording.
- ✓Three questions expose the differences: drug funding rules, aftercare limits, and monitoring cover.
Why cancer cover is where policies differ most
For most claims, private health insurance buys speed on things the NHS would eventually do anyway. Cancer is different in two ways. First, scale: a course of private cancer treatment can run from tens of thousands of pounds into six figures, making it the claim that most tests a policy's limits. Second, access: some newer cancer drugs and targeted therapies are licensed but not yet routinely funded on the NHS — meaning good private cover can buy treatments, not just timing.
It's worth being fair to the NHS here: cancer is treated with genuine urgency, outside the routine elective queues, and NHS oncology is world-class. The honest case for private cancer cover is about the margins that matter — faster diagnostics when symptoms first appear (around 1 in 4 people wait 6+ weeks for key NHS diagnostic tests), broader drug access, continuity with one named oncologist, and comfort factors during a hard year.
How the six major insurers approach cancer
In general terms — exact benefits vary by product, options and policy year, so always confirm against current documents:
| Insurer | General approach to cancer cover |
|---|---|
| Bupa | Long-standing comprehensive cancer promise on main options: eligible treatment covered from diagnosis, including some drugs not routinely NHS-funded, without an overall time limit on eligible treatment |
| AXA Health | Strong cancer cover on comprehensive plans, spanning diagnosis, treatment and follow-up; optional extras extend support |
| Aviva | Full cancer cover option covering eligible treatment and drugs; configurable alongside its modular Healthier Solutions product |
| Vitality | Advanced cancer cover on eligible plans, positioned around access to newer treatments and drugs alongside its wellness programme |
| WPA | Comprehensive cancer benefit on its main plans, with the insurer's characteristic shared-responsibility (co-payment) options |
| The Exeter | Cancer cover included within its straightforward comprehensive plans; a simpler product range with fewer variants to decode |
The honest summary: at comprehensive level, all six offer cancer cover a reasonable person would call strong, and none should be ruled out on headline alone. Rankings that declare a single "best" insurer for cancer usually dissolve on contact with the policy documents — what differs is structure and wording, which is why the questions in the next sections matter more than any league table.
Full, capped and NHS-linked: know which you're buying
Beneath the headlines, cancer benefits come in three broad shapes across the market:
- Full cancer cover. Eligible treatment covered in full from diagnosis onward — surgery, radiotherapy, chemotherapy and eligible drugs — without monetary caps on core treatment. This is the comprehensive-tier standard at major insurers.
- Capped or limited cover. Some budget products and older policies cap cancer benefits in money or time, or restrict certain treatment stages. The premium saving is real; so is the exposure, because cancer is precisely the claim that exceeds caps.
- NHS-linked options. Some products cover cancer privately only in defined circumstances, or top up NHS care — for example covering drugs the NHS won't fund while treatment otherwise stays on the NHS. Cheaper, and genuinely useful, but a different promise from full private oncology.
None of these is a trick — each is a legitimate price point. The mistake is paying budget premiums while believing you hold the full promise. If cancer cover is the main reason you're buying health insurance, that's a strong argument for a comprehensive policy rather than the cheapest quote on the page.
Compare cancer cover across six insurers
The questions that separate strong cover from adequate
Put these to any insurer (or broker) before you buy — the answers vary more than the brochures suggest:
- Drug funding. Are licensed cancer drugs covered when used outside NHS routine funding? Any monetary or time limits on drug therapy? What about off-label use a consultant recommends?
- Aftercare and follow-up. How long is monitoring covered after treatment ends — scans, consultations, blood tests? Is there a time or money limit on follow-up?
- Recurrence. If cancer returns years later, is it covered as part of the original claim or assessed afresh?
- Genetic and preventive nuance. If testing reveals high genetic risk, is preventive (risk-reducing) treatment covered? Policies differ here more than almost anywhere — many cover treatment of disease, not prevention of it — so ask for the wording.
- End-of-treatment support. Palliative care, home nursing, psychological support: covered, capped, or excluded?
One structural point sits behind all five: insurance covers cancer that arises after you join. A previous cancer will generally be excluded as pre-existing on a new personal policy — if that's your situation, our guide to cover after cancer walks through the honest options, including group schemes that disregard medical history.
How to actually choose
A sensible buying sequence: decide comprehensive versus budget first (if cancer cover drives the purchase, comprehensive), then get matched quotes from at least three of the six majors, then read the cancer sections of the front-runners side by side with the five questions above in hand. Premiums for comprehensive cover average around £80 a month for a UK adult, rising with age — the cancer wording rarely adds much between comparable tiers, so you're choosing on terms, not price.
And keep perspective: every policy here sits on top of an NHS that treats cancer urgently and well. Private cancer cover is a genuine upgrade at the margins that matter most — drug access, diagnostic speed, continuity — not a rescue from an absent safety net. Buy it, if you buy it, with that clear-eyed understanding.
Frequently asked questions
Which UK health insurer has the best cancer cover?
At comprehensive level, no single insurer dominates: Bupa, AXA Health, Aviva, Vitality, WPA and The Exeter all offer cancer cover spanning diagnosis, treatment and eligible drugs, and each structures it slightly differently. The better question is which policy's cancer wording best answers your questions on drug funding, aftercare and recurrence — that comparison produces a personal winner, not a universal one.
Does private health insurance cover cancer drugs the NHS won't fund?
Often, yes — this is one of the strongest arguments for comprehensive cancer cover. Major insurers generally cover licensed cancer drugs used for eligible treatment even where NHS routine funding hasn't caught up, subject to policy terms. Coverage rules for off-label use and any time or monetary limits vary by insurer, so ask for the drug-funding wording specifically.
What's the difference between full and NHS-linked cancer cover?
Full cancer cover pays for eligible private treatment from diagnosis onward — surgery, radiotherapy, chemotherapy, drugs — without monetary caps on core treatment. NHS-linked options are cheaper and cover cancer privately only in defined circumstances, or top up NHS care, for instance funding drugs the NHS won't while treatment otherwise stays on the NHS. Both are legitimate; know which you're buying.
Is cancer aftercare covered by health insurance?
It varies more than headline cover does. Insurers differ on how long they fund post-treatment monitoring — scans, consultations, blood tests — and on palliative care, home nursing and psychological support, any of which may be covered, capped or excluded. Aftercare wording is one of the clearest separators between cancer propositions, so put it on your question list before buying.
Does health insurance cover preventive surgery for genetic cancer risk?
Not reliably — this is one of the biggest gaps between policies. Many cover treatment of diagnosed cancer but not risk-reducing surgery for someone with a high-risk genetic result, while some insurers offer defined preventive benefits. If family history or genetic risk is your motivation for buying cancer cover, ask this question explicitly and get the answer in writing.
Will a new policy cover cancer I've had before?
Generally no — a previous cancer is a pre-existing condition and will be excluded on a new personal policy, at least initially. Everything unrelated remains covered, and group schemes through work on medical history disregarded terms can cover you in full regardless of history. Our cover-after-cancer guide sets out the honest options in detail.
Is it worth buying health insurance mainly for the cancer cover?
It's a coherent reason — cancer is where private cover adds treatments (newer drugs), not just speed, and diagnosis benefits from private diagnostics when around 1 in 4 NHS patients wait 6+ weeks for key tests. The honest caveats: the NHS already treats cancer urgently and well, and cancer-driven buyers should choose comprehensive cover, since capped options fail exactly this scenario.
Do budget health insurance policies include cancer cover?
Sometimes, but read carefully: budget products may cap cancer benefits in money or time, restrict treatment stages, or link cover to NHS provision. A low outpatient limit can also slow the diagnostic phase even when treatment cover is full. If cancer protection is a priority, the saving from a budget policy is usually the wrong saving.
How do Vitality and WPA compare with Bupa on cancer cover?
In general terms: Bupa's comprehensive options carry its long-standing cancer promise with no overall time limit on eligible treatment; Vitality positions its advanced cancer cover around access to newer treatments alongside its wellness programme; WPA offers comprehensive cancer benefit with its characteristic co-payment options. All three are credible — differences emerge in drug-funding, aftercare and monitoring wording rather than headlines.